Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):16–21. doi: 10.1054/bjoc.1999.1220

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma

E F McClay 1, M E T McClay 1, L Monroe 2, P L Baron 2, D J Cole 2, P H O'Brien 2, J S Metcalf 2, J C Maize 2
PMCID: PMC2374536  PMID: 10883662

Abstract

The adjuvant treatment of high-risk malignant melanoma remains problematic. Previously we reported moderate success in the treatment of metastatic disease using tamoxifen, cisplatin, dacarbazine and carmustine. Based upon data that suggested tamoxifen and cisplatin were the active agents in this regimen, we initiated a phase II trial of this combination in the adjuvant setting. We treated 153 patients with 4 cycles of tamoxifen (160 mg day–1, days 1–7) and cisplatin (100 mg m–2, day 2) for 28-day intervals. Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron. During the first 2 years of follow-up, patients were evaluated every 2 months with a history, physical exam, laboratory work and computed tomography scans of the chest, abdomen and pelvis every 4 months. Thereafter, patients were evaluated every 3 months and radiographic studies were performed if necessary. Currently, with a median follow-up of 36 months, the disease-free survival (DFS) is 68.4% and overall survival (OS) is 84.5%. Kaplan–Meier analysis predicts a 5-year DFS of 62% with an OS of 79%. Relapses after 20 months have been rare. No effect of gender or number of positive lymph nodes was noted, however, stage of disease prior treatment was a factor. The major toxicity proved to be gastrointestinal in nature with nausea the most prevalent symptom. Minimal renal, haematologic and neurologic toxicity occurred. These preliminary results suggest that there is a positive impact of tamoxifen and cisplatin on both the DFS and OS of high-risk malignant melanoma patients. The 5-year projected DFS and OS compare favourably with those reported for the ECOG 1684 trial and warrant confirmation in a prospective randomized trial. © 2000 Cancer Research Campaign

Keywords: tamoxifen, cisplatin, adjuvant therapy, melanoma

Full Text

The Full Text of this article is available as a PDF (77.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson C. M., Buzaid A. C., Legha S. S. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8. [PubMed] [Google Scholar]
  2. Cascinelli N., Bufalino R., Morabito A., Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994 Apr 9;343(8902):913–914. doi: 10.1016/s0140-6736(94)90030-2. [DOI] [PubMed] [Google Scholar]
  3. Clark W. H., Jr, Elder D. E., Guerry D., 4th, Braitman L. E., Trock B. J., Schultz D., Synnestvedt M., Halpern A. C. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989 Dec 20;81(24):1893–1904. doi: 10.1093/jnci/81.24.1893. [DOI] [PubMed] [Google Scholar]
  4. Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., Buzzi F., Ceci G., Corgna E., Costa P. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516–523. doi: 10.1056/NEJM199208203270803. [DOI] [PubMed] [Google Scholar]
  5. Cole B. F., Gelber R. D., Kirkwood J. M., Goldhirsch A., Barylak E., Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct;14(10):2666–2673. doi: 10.1200/JCO.1996.14.10.2666. [DOI] [PubMed] [Google Scholar]
  6. Creagan E. T., Dalton R. J., Ahmann D. L., Jung S. H., Morton R. F., Langdon R. M., Jr, Kugler J., Rodrigue L. J. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995 Nov;13(11):2776–2783. doi: 10.1200/JCO.1995.13.11.2776. [DOI] [PubMed] [Google Scholar]
  7. Creagan E. T., Suman V. J., Dalton R. J., Pitot H. C., Long H. J., Veeder M. H., Vukov A. M., Rowland K. M., Krook J. E., Michalak J. C. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884–1890. doi: 10.1200/JCO.1999.17.6.1884. [DOI] [PubMed] [Google Scholar]
  8. Czarnetzki B. M., Macher E., Suciu S., Thomas D., Steerenberg P. A., Rümke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer. 1993;29A(9):1237–1242. doi: 10.1016/0959-8049(93)90064-m. [DOI] [PubMed] [Google Scholar]
  9. Del Prete S. A., Maurer L. H., O'Donnell J., Forcier R. J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984 Nov;68(11):1403–1405. [PubMed] [Google Scholar]
  10. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  11. Mc Clay E. F., Mc Clay M. E., Albright K. D., Jones J. A., Christen R. D., Alcaraz J., Howell S. B. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer. 1993 Sep 15;72(6):1914–1918. doi: 10.1002/1097-0142(19930915)72:6<1914::aid-cncr2820720620>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  12. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer. 1994 Sep;70(3):449–452. doi: 10.1038/bjc.1994.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer. 1993 Dec 2;55(6):1018–1022. doi: 10.1002/ijc.2910550623. [DOI] [PubMed] [Google Scholar]
  14. McClay E. F., Albright K. D., Jones J. A., Christen R. D., Howell S. B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res. 1993 Apr 1;53(7):1571–1576. [PubMed] [Google Scholar]
  15. McClay E. F., Albright K. D., Jones J. A., Eastman A., Christen R., Howell S. B. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 1992 Dec 15;52(24):6790–6796. [PubMed] [Google Scholar]
  16. McClay E. F., Mastrangelo M. J., Bellet R. E., Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep. 1987 May;71(5):465–469. [PubMed] [Google Scholar]
  17. McClay E. F., Mastrangelo M. J., Berd D., Bellet R. E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992 Feb 20;50(4):553–556. doi: 10.1002/ijc.2910500410. [DOI] [PubMed] [Google Scholar]
  18. McClay E. F., Mastrangelo M. J., Sprandio J. D., Bellet R. E., Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer. 1989 Apr 1;63(7):1292–1295. doi: 10.1002/1097-0142(19890401)63:7<1292::aid-cncr2820630711>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  19. Pectasides D., Alevizakos N., Bafaloukos D., Tzonou A., Asimakopoulos G., Varthalitis I., Dimitriadis M., Athanassiou A. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol. 1994 Feb;17(1):55–59. doi: 10.1097/00000421-199402000-00012. [DOI] [PubMed] [Google Scholar]
  20. Pehamberger H., Soyer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Auböck J., Fritsch P., Kerl H. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998 Apr;16(4):1425–1429. doi: 10.1200/JCO.1998.16.4.1425. [DOI] [PubMed] [Google Scholar]
  21. Quirt I. C., Shelley W. E., Pater J. L., Bodurtha A. J., McCulloch P. B., McPherson T. A., Paterson A. H., Prentice R., Silver H. K., Willan A. R. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991 May;9(5):729–735. doi: 10.1200/JCO.1991.9.5.729. [DOI] [PubMed] [Google Scholar]
  22. Retsas S., Quigley M., Pectasides D., Macrae K., Henry K. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer. 1994 Apr 15;73(8):2119–2130. doi: 10.1002/1097-0142(19940415)73:8<2119::aid-cncr2820730817>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  23. Richards J. M., Gilewski T. A., Ramming K., Mitchel B., Doane L. L., Vogelzang N. J. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer. 1992 Jan 15;69(2):427–429. doi: 10.1002/1097-0142(19920115)69:2<427::aid-cncr2820690225>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  24. Rusthoven J. J., Quirt I. C., Iscoe N. A., McCulloch P. B., James K. W., Lohmann R. C., Jensen J., Burdette-Radoux S., Bodurtha A. J., Silver H. K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Jul;14(7):2083–2090. doi: 10.1200/JCO.1996.14.7.2083. [DOI] [PubMed] [Google Scholar]
  25. Saba H. I., Cruse C. W., Wells K. E., Klein C. J., Reintgen D. S. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg. 1992 Jan;28(1):65–69. doi: 10.1097/00000637-199201000-00017. [DOI] [PubMed] [Google Scholar]
  26. Spitler L. E. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol. 1991 May;9(5):736–740. doi: 10.1200/JCO.1991.9.5.736. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES